Background: Severe malaria is a medical emergency with high mortality. Prompt achievement of therapeutic concentrations of highly effective anti-malarial drugs reduces the risk of death. The aim of this study was to assess the pharmacokinetics and pharmacodynamics of intravenous artesunate in Ugandan adults with severe malaria.

Methods: Fourteen adults with severe falciparum malaria requiring parenteral therapy were treated with 2.4 mg/kg intravenous artesunate. Blood samples were collected after the initial dose and plasma concentrations of artesunate and dihydroartemisinin measured by solid-phase extraction and liquid chromatography-tandem mass spectrometry. The study was approved by the Makerere University Faculty of Medicine Research and Ethics Committee (Ref2010-015) and Uganda National Council of Science and Technology (HS605) and registered with ClinicalTrials.gov (NCT01122134).

Results: All study participants achieved prompt resolution of symptoms and complete parasite clearance with median (range) parasite clearance time of 17 (8-24) hours. Median (range) maximal artesunate concentration (Cmax) was 3260 (1020-164000) ng/mL, terminal elimination half-life (T1/2) was 0.25 (0.1-1.8) hours and total artesunate exposure (AUC) was 727 (290-111256) ng·h/mL. Median (range) dihydroartemisinin Cmax was 3140 (1670-9530) ng/mL, with Tmax of 0.14 (0.6 - 6.07) hours and T1/2 of 1.31 (0.8-2.8) hours. Dihydroartemisinin AUC was 3492 (2183-6338) ng·h/mL. None of the participants reported adverse events.

Conclusions: Plasma concentrations of artesunate and dihydroartemisinin were achieved rapidly with rapid and complete symptom resolution and parasite clearance with no adverse events.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3489518PMC
http://dx.doi.org/10.1186/1475-2875-11-132DOI Listing

Publication Analysis

Top Keywords

intravenous artesunate
12
parasite clearance
12
median range
12
pharmacokinetics pharmacodynamics
8
pharmacodynamics intravenous
8
severe malaria
8
ugandan adults
8
adults severe
8
plasma concentrations
8
concentrations artesunate
8

Similar Publications

Malaria, a mosquito-borne disease caused by five plasmodium species, still has a life-threatening risk worldwide. Clinical manifestations can range from mild nonspecific symptoms to severe disease. In non-endemic regions, sporadic cases frequently pose significant challenges to health workers as delayed diagnosis can lead to serious consequences and even death.

View Article and Find Full Text PDF
Article Synopsis
  • A 52-year-old man was admitted to the ICU in septic shock from severe malaria after traveling to Ghana, with a high parasitaemia index of 50%.
  • He was treated with intravenous artesunate and dihydroartemisinin plus piperaquine, leading to rapid clinical improvement and a 0% parasitaemia level within 72 hours, but developed severe anaemia with hemoglobin dropping to 5.6 g/dL.
  • The anaemia was diagnosed as post-artesunate haemolytic anaemia (PDAH) due to high parasitaemia and treatment, treated with oral steroids, highlighting the need for awareness of PDAH in severe malaria cases for effective recovery.
View Article and Find Full Text PDF
Article Synopsis
  • Malaria has surged in sub-Saharan Africa due to disruptions from the Covid-19 pandemic, leading to severe cases like cerebral malaria and acute kidney injury.
  • A 22-year-old male from Chad, who presented with confusion and had a history of travel to an endemic area, was initially misdiagnosed but later confirmed to have malaria with severe symptoms.
  • Successful treatment included intravenous artesunate and hemodialysis, and the patient was discharged after 20 days, highlighting the need for quick diagnosis and effective management of malaria complications.
View Article and Find Full Text PDF

In patients presenting with post-malarial anemia following intravenous artesunate treatment, post-artesunate delayed hemolysis should be considered in the differential diagnosis, even in endemic settings. Close monitoring for signs of delayed hemolysis in patients previously treated with intravenous artesunate for severe malaria, regardless of their malaria exposure history or geographic location is crucial.

View Article and Find Full Text PDF

Malaria is an infection caused by five different Plasmodium species. The most common are is more rarely reported and mostly has a benign course. We present a case of a 40-year-old male with a six-day history of headaches, chills, and fever who was initially evaluated in our emergency room, from where he was discharged after a negative workup for malaria.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!